Shamburg News · 8-K filed Nov 5, 2026, 4:33 PM EST
Pacira BioSciences Withdraws 2026 Guidance and Will Skip Q3 Earnings Amid Viatris Tender Offer
PCRX · Pacira BioSciences, Inc.
- Acquisition
- Other event
- Reg FD disclosure
- Materiality: high
Pacira BioSciences disclosed that Viatris subsidiary Peach Purchaser Sub Inc. commenced a tender offer on October 30, 2026 for all outstanding Shares at $36.50 per Share in cash, pursuant to an October 8, 2026 merger agreement. The company will not issue an earnings release or hold a conference call for the quarter ended September 30, 2026. Pacira also withdrew its previously issued 2026 financial guidance and will not update it during the pendency of the offer and merger.
Source: SEC EDGAR, Form 8-K, Items 7.01, 9.01, accession 0001628280-26-071129.
Written from the filing by Shamburg Markets. Figures are as reported by the company.